About
Technology
Issues
FAQ
Links
Official Page
Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.